60 Degrees Pharmaceuticals (SXTP) EBT Margin (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly EBT Margin of 1289.49% for Q1 2026, down 14166.0% year-over-year from N/an in Q1 2025, and down 298.66% quarter-over-quarter from 323.45% in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) EBT Margin (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported EBT Margin for 5 consecutive years, with 1289.49% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 14166.0% year-over-year to 1289.49%; the TTM figure through Mar 2026 stood at 709.32% (up 83264.0% YoY), while the FY2025 annual figure was 687.12%, up 62230.0% from the prior year.
- EBT Margin eased to 1289.49% in Q1 2026 per SXTP's latest filing, from 323.45% in the prior quarter.
- Across five years, EBT Margin topped out at 8153.48% in Q3 2023 and bottomed at 15126.2% in Q1 2023.
- Historically, EBT Margin has averaged 1349.17% across 5 years, with a median of 848.25% in 2024.
- On a YoY basis, EBT Margin climbed as much as 1553126 bps in 2024 and fell as far as 975020 bps in 2024.
- 60 Degrees Pharmaceuticals' EBT Margin stood at 862.39% in 2022, then grew by 13 bps to 752.73% in 2023, then declined by 13 bps to 848.25% in 2024, then jumped by 62 bps to 323.45% in 2025, then sank by 299 bps to 1289.49% in 2026.
- Business Quant data shows SXTP's EBT Margin at 1289.49% in Q1 2026, 323.45% in Q4 2025, and 529.43% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -1,089.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,289.49% |
| Dec 31, 2025 | -323.45% |
| Sep 30, 2025 | -529.43% |
| Jun 30, 2025 | -1,717.42% |
| Mar 31, 2025 | -1,147.83% |
| Dec 31, 2024 | -848.25% |
| Sep 30, 2024 | -1,596.72% |
| Jun 30, 2024 | -3,339.78% |
| Mar 31, 2024 | 405.06% |
| Dec 31, 2023 | -752.73% |
| Sep 30, 2023 | 8,153.48% |
| Jun 30, 2023 | -836.46% |
| Mar 31, 2023 | -15,126.20% |
| Sep 30, 2022 | -862.39% |
| Jun 30, 2022 | -426.02% |